Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must be over 18 years old
- You are being considered for a major surgery to remove part of the liver
- You have bowel (colorectal) cancer that has spread to the liver, and that spread can be removed with surgery
Who may not be able to join:
- You are not able to give your consent to take part in the trial
- You have Type 1 diabetes
- Your blood sugar levels are not well controlled (specifically, fasting blood sugar is above a certain level — confirm with trial site)
- The bowel cancer that has spread to your liver cannot be removed with surgery
- You have bowel cancer that has spread to other parts of the body beyond the liver, and that spread cannot be removed with surgery
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 514-934-1934
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Liver function improvement after high-dose insulin therapy measured with 99mTc-Mebrofenin Hepatobiliary Scintigraphy (HBS).; Liver function improvement after high-dose insulin therapy after LVD measured with 99mTc-Mebrofenin Hepatobiliary Scintigraphy (HBS).; Liver regeneration improvement after high-dose insulin therapy after LVD measured CT volumetry
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.